Therefore, we questioned whether activation of the CD137:CD137L co-stimulatory pathway would enhance immune clearance of HPV (+) cancers either as a single agent, in combination with CRT, and when expressed locally by the tumor cells themselves (i.e., not administered systemically). Here, TNFRSF9 is linked to cancer.